top of page
  • Writer's pictureKendall
    • Jan 21, 2014

Friedreich's Ataxia Treatment Advancement


The Friedreich's Ataxia Research Alliance announced today that BioMarin Pharmaceutical, a company with a strong commitment and success in developing treatments for rare diseases, will be taking the Histone DeACetylase (HDAC) inhibitor program forward. Click here to access FARA's press release as well as a press release from Repligen and BioMarin.

With this exciting news, we are reminded of the important work our donations fund. Thank you to everyone who has had a part in making this happen. We are moving forward to finding a cure for Friedreich's Ataxia!

1 view0 comments

Recent Posts

See All

How I adjust to my summer 2023 body

I am a freelance columnist for Friedreich's Ataxia News. I was recently published on my column, My Darling Disability, and I wanted to share it here, too. You can either read it by following this link

Why perseverance is important in life with FA

I am a freelance columnist for Friedreich's Ataxia News. I was recently published on my column, My Darling Disability, and I wanted to share it here, too. You can either read it by following this link

What it’s like to have an ambulatory disability

I am a freelance columnist for Friedreich's Ataxia News. I was recently published on my column, My Darling Disability, and I wanted to share it here, too. You can either read it by following this link

bottom of page